WO2003068164A3 - Dosing regimen for gemcitabine hcv therapy - Google Patents

Dosing regimen for gemcitabine hcv therapy Download PDF

Info

Publication number
WO2003068164A3
WO2003068164A3 PCT/US2003/004481 US0304481W WO03068164A3 WO 2003068164 A3 WO2003068164 A3 WO 2003068164A3 US 0304481 W US0304481 W US 0304481W WO 03068164 A3 WO03068164 A3 WO 03068164A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapy
days
gemcitabine
viral
dosing regimen
Prior art date
Application number
PCT/US2003/004481
Other languages
French (fr)
Other versions
WO2003068164A2 (en
Inventor
Lieven J Stuyver
Original Assignee
Pharmasset Ltd
Lieven J Stuyver
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmasset Ltd, Lieven J Stuyver filed Critical Pharmasset Ltd
Priority to JP2003567349A priority Critical patent/JP2006505490A/en
Priority to CA002476282A priority patent/CA2476282A1/en
Priority to EP03713459A priority patent/EP1482943A2/en
Priority to MXPA04007878A priority patent/MXPA04007878A/en
Priority to KR10-2004-7012662A priority patent/KR20040091052A/en
Priority to AU2003217414A priority patent/AU2003217414A1/en
Publication of WO2003068164A2 publication Critical patent/WO2003068164A2/en
Publication of WO2003068164A3 publication Critical patent/WO2003068164A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Abstract

A dosage regiment for the treatment of a Flaviviridae infection, including a hepatitis C viral infection, that includes administering gemcitabine (or its salt, prodrug or derivative, as described herein) in a dosage range of approximately 50 mg/m2 per day for between one and seven days (e.g. 1, 2, 3, 4, 5, 6, or 7 days) followed ba cessation of therapy. Viral load is optionally monitored over time, and after cessation, viral rebound is monitored. Therapy is not resumed unless a significant viral load is again observed, and then therapy for 1-7 days and more preferred, 1, 2 or 3 days is repeated. This therapy can be continued indefinitely to monitor and maintain the health of the patient.
PCT/US2003/004481 2002-02-14 2003-02-14 Dosing regimen for gemcitabine hcv therapy WO2003068164A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2003567349A JP2006505490A (en) 2002-02-14 2003-02-14 Dosage plan for gemcitabine HCV treatment
CA002476282A CA2476282A1 (en) 2002-02-14 2003-02-14 Dosing regimen for gemcitabine hcv therapy
EP03713459A EP1482943A2 (en) 2002-02-14 2003-02-14 Dosing regimen for gemcitabine hcv therapy
MXPA04007878A MXPA04007878A (en) 2002-02-14 2003-02-14 Dosing regimen for gemcitabine hcv therapy.
KR10-2004-7012662A KR20040091052A (en) 2002-02-14 2003-02-14 Dosing regimen for gemcitabine HCV therapy
AU2003217414A AU2003217414A1 (en) 2002-02-14 2003-02-14 Dosing regimen for gemcitabine hcv therapy

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35741102P 2002-02-14 2002-02-14
US60/357,411 2002-02-14
US35814002P 2002-02-20 2002-02-20
US60/358,140 2002-02-20

Publications (2)

Publication Number Publication Date
WO2003068164A2 WO2003068164A2 (en) 2003-08-21
WO2003068164A3 true WO2003068164A3 (en) 2004-03-11

Family

ID=27737594

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2003/004379 WO2003068162A2 (en) 2002-02-14 2003-02-13 Modified fluorinated nucleoside analogues
PCT/US2003/004481 WO2003068164A2 (en) 2002-02-14 2003-02-14 Dosing regimen for gemcitabine hcv therapy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2003/004379 WO2003068162A2 (en) 2002-02-14 2003-02-13 Modified fluorinated nucleoside analogues

Country Status (12)

Country Link
US (2) US20040002476A1 (en)
EP (2) EP1480982A4 (en)
JP (2) JP2005522443A (en)
KR (2) KR20040094692A (en)
CN (2) CN1646534A (en)
AU (2) AU2003217402A1 (en)
BR (1) BR0307712A (en)
CA (2) CA2476279A1 (en)
MX (2) MXPA04007876A (en)
NZ (1) NZ534811A (en)
WO (2) WO2003068162A2 (en)
ZA (1) ZA200406858B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9186369B2 (en) 2003-07-25 2015-11-17 Idenix Pharmaceuticals, Llc Purine nucleoside analogues for treating flaviviridae including hepatitis C

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60136620D1 (en) 2000-04-13 2009-01-02 Pharmasset Inc 3 OR 2 HYDROXYMETHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF VIRUS INFECTIONS
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EP1736478B1 (en) 2000-05-26 2015-07-22 IDENIX Pharmaceuticals, Inc. Methods and compositions for treating flaviviruses and pestiviruses
AU2002330154A1 (en) * 2001-09-28 2003-04-07 Centre National De La Recherche Scientifique Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
US20030180279A1 (en) * 2002-03-19 2003-09-25 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
US20040197321A1 (en) * 2002-03-19 2004-10-07 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
US7608600B2 (en) * 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
CN101172993A (en) * 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
AP2005003213A0 (en) * 2002-06-28 2005-03-31 Univ Cagliari 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections.
US20040067877A1 (en) 2002-08-01 2004-04-08 Schinazi Raymond F. 2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections
IL166640A0 (en) 2002-08-01 2006-01-15 Pharmasset Ltd Compounds with the bicyclo Ä4.2.1Ü nonane system for the treatment of flaviviridae infections
HUE033832T2 (en) 2002-11-15 2018-01-29 Idenix Pharmaceuticals Llc 2'-methyl nucleosides in combination with interferon and flaviviridae mutation
CA2509687C (en) * 2002-12-12 2012-08-14 Idenix (Cayman) Limited Process for the production of 2'-branched nucleosides
PL377608A1 (en) * 2002-12-23 2006-02-06 Idenix (Cayman) Limited Process for the production of 3'-nucleoside prodrugs
MXPA05010419A (en) * 2003-03-28 2006-05-31 Pharmasset Inc Compounds for the treatment of flaviviridae infections.
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
WO2005018330A1 (en) * 2003-08-18 2005-03-03 Pharmasset, Inc. Dosing regimen for flaviviridae therapy
RU2007102281A (en) * 2004-06-23 2008-07-27 Айденикс (Кайман) Лимитед (Ky) 5-AZA-7-DEAZAPURINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH FLAVIVIRIDAE
US7524831B2 (en) * 2005-03-02 2009-04-28 Schering Corporation Treatments for Flaviviridae virus infection
MX2007015534A (en) 2005-06-07 2008-02-25 Univ Yale Methods of treating cancer and other conditions or disease states using lfmau and ldt.
EP1968595A4 (en) * 2005-12-02 2014-05-21 Univ Yale Methods of treating cancer and other conditions or disease states using l-cytosine nucleoside analogs
CA2634749C (en) * 2005-12-23 2014-08-19 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
GB0623493D0 (en) 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
US8188104B2 (en) * 2007-09-17 2012-05-29 Abbott Laboratories Anti-infective agents and uses thereof
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
US20100021505A1 (en) * 2008-07-28 2010-01-28 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
CN102216316A (en) 2008-09-05 2011-10-12 寿制药株式会社 Substituted amine derivative and medicinal composition comprising same as the active ingredient
US20110306541A1 (en) * 2010-06-10 2011-12-15 Gilead Sciences, Inc. Methods for treating hcv
WO2014070771A1 (en) * 2012-10-29 2014-05-08 Rfs Pharma, Llc Pyrimidine nucleotides and their monophosphate prodrugs for treatment of viral infections and cancer
HUE044605T2 (en) 2012-11-16 2019-11-28 Univ College Cardiff Consultants Ltd Mixture of rp/sp gemcitabine-[phenyl-(benzyloxy-l-alaninyl)]-phosphate
BR112015025716A2 (en) 2013-04-12 2017-07-18 Achillion Pharmaceuticals Inc Deuterium Nucleoside Prodrugs Useful for Hcv Treatment
CA2994502C (en) 2015-10-05 2023-08-01 NuCana plc Combination therapy comprising nuc-1031 and carboplatin for cancer treatment
WO2018200859A1 (en) * 2017-04-26 2018-11-01 Kalman Thomas I Multitargeted nucleoside derivatives
JP2020125245A (en) * 2019-02-01 2020-08-20 ダイキン工業株式会社 Anti-hepatitis C virus agent

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000021565A1 (en) * 1998-10-13 2000-04-20 Du Pont Pharmaceuticals Company Selective eradication of virally-infected cells by combined use of a cytotoxic agent and an antiviral agent

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) * 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
EP0184365B1 (en) * 1984-12-04 1993-08-04 Eli Lilly And Company Improvements in the treatment of tumors in mammals
GB8719367D0 (en) * 1987-08-15 1987-09-23 Wellcome Found Therapeutic compounds
HU204843B (en) * 1988-09-27 1992-02-28 Merrell Dow Pharma Process for producing 2'-halogen-methylidene adenosine derivatives and pharmaceutical compositions comprising same
ZA898567B (en) * 1988-11-15 1990-08-29 Merrell Dow Pharma Novel 2'-halomethylidene,2'-ethenylidene and 2'-ethynyl cytidine,uridine and guanosine derivatives
US5616702A (en) * 1988-11-15 1997-04-01 Merrell Pharmaceuticals Inc. 2-'-ethenylidene cytidine, uridine and guanosine derivatives
US5705363A (en) * 1989-03-02 1998-01-06 The Women's Research Institute Recombinant production of human interferon τ polypeptides and nucleic acids
US5026687A (en) * 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
TW224053B (en) * 1991-09-13 1994-05-21 Paul B Chretien
DK0664708T3 (en) * 1992-04-10 1998-11-02 Merrell Pharma Inc Method of treating cancer by combination therapy with 2'-halomethylidene derivatives and an S-phase or M-phase spec
EP0640092B1 (en) * 1992-05-12 1996-12-11 Merrell Pharmaceuticals Inc. A process for the preparation of ribonucleotide reductase inhibitors
YU43193A (en) * 1992-06-22 1997-01-08 Eli Lilly And Company 2'-DEOXY-2 ', 2'-DIFLUORO (4-SUBSTITUTED) PYRIMIDINE NUCLEOSIDS OF ANTIVIRUS AND ANTICANCEROGENIC ACTIVITY AND INTERMEDIATES
CA2156394A1 (en) * 1993-02-24 1994-09-01 Jui H. Wang Compositions and methods of application of reactive antiviral polymers
WO1995003056A1 (en) * 1993-07-19 1995-02-02 Tokyo Tanabe Company Limited Hepatitis c virus proliferation inhibitor
DE4432623A1 (en) * 1994-09-14 1996-03-21 Huels Chemische Werke Ag Process for bleaching aqueous surfactant solutions
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
GB9601680D0 (en) * 1996-01-27 1996-03-27 Pfizer Ltd Therapeutic agents
US5980884A (en) * 1996-02-05 1999-11-09 Amgen, Inc. Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
US5830905A (en) * 1996-03-29 1998-11-03 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
US5891874A (en) * 1996-06-05 1999-04-06 Eli Lilly And Company Anti-viral compound
US5922757A (en) * 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders
UA61962C2 (en) * 1997-06-30 2003-12-15 Мерц Фарма Гмбх Унд Ко. Кгаа 1-amino-alkylcyclohexane nmda receptors antagonists
CA2322008C (en) * 1998-02-25 2011-06-28 Emory University 2'-fluoronucleosides
GB9806815D0 (en) * 1998-03-30 1998-05-27 Hoffmann La Roche Amino acid derivatives
TW466112B (en) * 1998-04-14 2001-12-01 Lilly Co Eli Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same
EA200200778A1 (en) * 2000-02-18 2003-06-26 Шайре Байокем Инк. METHOD OF TREATMENT OR PREVENTION OF HEPATITIS C INFECTION IN THE ORGANISM ORGANISM, PHARMACEUTICAL COMPOSITION AGAINST FLAVIVIRUS, CONNECTION OF FORMULA Ib - AN ACTIVE AGENT FOR THE TREATMENT OR PREVENTION OF EFFECTECH EFFECTURES Ib - AN ACTIVE AGENT FOR THE TREATMENT OR PREVENTION INEKEKHEKUSA Ib - AN ACTIVE AGENT FOR THE TREATMENT OR PROTECTION
US20020052317A1 (en) * 2000-08-02 2002-05-02 Loretta Itri Anti-viral and anti-tumor chemotherapy by administration of erythropoeitin
US20030008841A1 (en) * 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
AU2002303187C1 (en) * 2001-03-30 2008-06-12 Bukwang Pharmaceutical Company Ltd Process for the preparation of 2'-HALO-Beta-L-arabinofuranosyl nucleosides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000021565A1 (en) * 1998-10-13 2000-04-20 Du Pont Pharmaceuticals Company Selective eradication of virally-infected cells by combined use of a cytotoxic agent and an antiviral agent

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9186369B2 (en) 2003-07-25 2015-11-17 Idenix Pharmaceuticals, Llc Purine nucleoside analogues for treating flaviviridae including hepatitis C

Also Published As

Publication number Publication date
NZ534811A (en) 2007-07-27
EP1480982A4 (en) 2007-08-01
MXPA04007878A (en) 2005-06-20
EP1480982A2 (en) 2004-12-01
JP2005522443A (en) 2005-07-28
KR20040094692A (en) 2004-11-10
CA2476282A1 (en) 2003-08-21
WO2003068164A2 (en) 2003-08-21
WO2003068162A3 (en) 2004-03-11
EP1482943A2 (en) 2004-12-08
ZA200406858B (en) 2005-09-28
CN1646534A (en) 2005-07-27
BR0307712A (en) 2005-05-24
JP2006505490A (en) 2006-02-16
CA2476279A1 (en) 2003-08-21
AU2003217402A1 (en) 2003-09-04
WO2003068162A2 (en) 2003-08-21
MXPA04007876A (en) 2005-06-20
AU2003217414A8 (en) 2003-09-04
KR20040091052A (en) 2004-10-27
US20040002476A1 (en) 2004-01-01
CN1646129A (en) 2005-07-27
US20030225029A1 (en) 2003-12-04
AU2003217414A1 (en) 2003-09-04

Similar Documents

Publication Publication Date Title
WO2003068164A3 (en) Dosing regimen for gemcitabine hcv therapy
AR048431A1 (en) GALENIC FORMULATIONS OF ORGANIC COMPOUNDS
WO2005020884A3 (en) Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses
TW200500375A (en) Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
NO20060981L (en) Pyridazine derivatives and their use as therapeutic agents
TW200505881A (en) Tri(cyclo) substituted amide compounds
RU2003131876A (en) COMPOSITIONS OF N-ACETYLCYSTEINE AND METHODS OF TREATMENT AND PREVENTION OF TOXICITY OF MEDICINES
WO2008054454A3 (en) Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents
TW200510391A (en) Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
HK1086186A1 (en) Use of spongosine (2-methoxyadenosein) for preparing pharmaceutical for the treatment of pain
NO20065904L (en) Therapeutic compounds
WO2005039485A3 (en) Gsk-3 inhibitors and uses thereof
WO2004032909A3 (en) Stabilized pharmaceutical composition containing basic excipients
MXPA03008623A (en) Pharmaceutical combinations for the treatment of cancer.
WO2007064448A3 (en) Cancer treatment using fts and 2-deoxyglucose
TNSN04203A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
HK1077215A1 (en) A pharmaceutical composition for treatment of acute myocardial infarction
JP2006514116A5 (en)
TW200501940A (en) Virus therapeutic drug
RU2006113366A (en) THERAPEUTIC TREATMENT
PE20040706A1 (en) SPECIFIC DERIVATIVE OF AMINE CYCLIC AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS INVOLVED IN THE PREVENTION OF HEART FAILURE
ATE545423T1 (en) AGENTS FOR THE TREATMENT OF LUNG CANCER
DE60321175D1 (en) DICHLORACETATE IN COMBINATION WITH CARDIOPROTECTIVES OR HEMODYNAMIC MEDICAMENTS
WO2005058248A3 (en) A method of treating hiv infection in atazanavir resistant patients using a combination of atazanavir and another protease inhibitor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/007878

Country of ref document: MX

Ref document number: 2003567349

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020047012662

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2476282

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003713459

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003808385X

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003713459

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003713459

Country of ref document: EP

ENPW Started to enter national phase and was withdrawn or failed for other reasons

Ref document number: PI0307709

Country of ref document: BR

Free format text: PEDIDO RETIRADO FACE A IMPOSSIBILIDADE DE ACEITACAO DA ENTRADA NA FASE NACIONAL POR TER SIDO INTEMPESTIVA. O PRAZO PARA ENTRADA NA FASE NACIONAL EXPIRAVA EM 14.10.2003 ( 20 MESES - BR DESIGNADO APENAS), ELEICAO NAO COMPROVADA, E A PRETENSA ENTRADA NA FASE NACIONAL SO OCORREU EM 16.08.2004.

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)